Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
345
resultados
Última actualización
16/10/2026 [07:35:00]
Resultados 100 a 125 de 345
Resumen de: US20260285954A1
The present invention relates to an improved antibody specifically binding to amyloid-β oligomers (AβOs). Specifically, the present invention relates to an improved form of the antibody W20. Compared with the antibody W20, the improved form of the antibody W20 has a significantly improved affinity to AβOs, and can more significantly inhibit the aggregation of Aβ and the AβOs-induced toxicity of nerve cells, more effectively improve the cognition and memory functions of an Alzheimer's disease model mouse, and reduce pathological changes in the brain of the mouse. The improved form of the antibody can specifically bind to oligomers of an amyloid-β, α-synuclein, mHTT and SOD 1, can inhibit the aggregation and cytotoxicity of various amyloids, and has a better potential for treating various amyloid diseases, such as Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis, than the antibody W20. The improved form of the antibody can specifically bind to a highly toxic amyloid protein oligomer Aβo*3F, and has a better AD diagnosis value. The amino acid sequence of the antibody W20 is as shown in SEQ ID NO: 1.
Resumen de: US20260286293A1
Disclosed herein are pluripotent stem cells cultured with one or more peptide and methods of isolating said stem cells. Also disclosed are methods of targeting the stem cells to a desired region or area within an organism. Also disclosed are methods of using the isolated stem cells for the improvement of fertility, for the promotion of hair growth, for the treatment or prevention of skin conditions, for the treatment or improvement of bone disorders, for the treatment of malignancies, and for the treatment of neurological disorders.
Resumen de: US20260284227A1
The present invention provides a method for providing modified mRNAs of reduced immunogenicity and/or immunostimulatory capacity for use in protein replacement therapy. The invention further provides modified mRNAs and pharmaceutical compositions comprising the modified mRNAs according to the invention for use in protein replacement therapy.
Resumen de: US20260286363A1
0000 The present disclosure provides compositions and methods of identifying, making, and using the same for the prevention and treatment of lysosomal storage diseases. Provided are also compositions and methods of diagnosing lysosomal storage diseases.
Resumen de: US20260287589A1
0000 Disclosures herein are directed to methods and compositions for predicting high- and low-risk liver disease in patients. Based on the results achieved from the methods and compositions disclosed herein, liver disease patients can be classified into a prognostic risk group, which enables early diagnosis and prevention of HCC and other lethal complications. Methods and compositions disclosed herein substantially improve the poor prognosis of subjects having or at risk for one or more liver diseases.
Resumen de: US20260287578A1
The anatomical model of a nasal cavity, such as a human nasal cavity, for in-vitro inhalation studies such as toxicological screening, intranasal drug delivery studies, and neurophysiological studies. The model includes a model body including separable upper and lower model portions together defining the nasal cavity and including fluidic channels therein that define an olfactory region of the upper model portion, and a nasal passage defined in the lower model portion. A biocompatible porous membrane is positioned between the upper and lower model portions, and the biocompatible membrane is configured for culturing olfactory epithelium cells thereon. An artificial mucous layer coats a surface of the nasal cavity and is configured to collect particles passing through the nasal cavity.
Resumen de: CN122794000A
本发明属于生物技术领域，具体涉及一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用。本发明一种脑脊液多肽标志物GHVLAKELE在制备神经梅毒诊断或筛查产品中的应用，诊断产品是以所述多肽或其特异性结合分子为靶分子的检测试剂盒、抗体芯片、抗体探针或检测仪。本发明克服了现有CSF‑TRUST敏感性低、常规指标特异性差的技术问题，且这种多肽标志物能够准确区分神经梅毒患者与非神经梅毒。
Resumen de: CN122790086A
0001 本发明公开了一种检测tau蛋白的抗体及其应用，涉及抗体领域。本发明公开的检测tau蛋白的抗体包括重链互补决定区和轻链互补决定区，该抗体为tau蛋白的检测提供了重要的原料来源，基于该抗体的检测，灵敏度高、特异性强，有助于阿尔茨海默病等相关疾病的预测、诊断、动态监测及预后评估，具有非常高的临床应用价值。
Resumen de: CN122790090A
0001 本发明涉及生物技术领域，具体涉及抗BD‑Tau蛋白单克隆抗体或其抗原结合片段及其应用。本发明提供的抗体对BD‑Tau蛋白具有高亲和力，能够特异性识别和结合BD‑Tau蛋白，可用于制备BD‑Tau检测试剂或试剂盒，在阿尔茨海默病的早期筛查和诊断中具有重要的应用价值。
Resumen de: US2019227064A1
0001 The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML).
Resumen de: AU2024398768A1
Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.
Resumen de: WO2025176707A1
The present invention relates to an agent that increases Nato3 expression and/or activity for use in preventing or treating a neurological disorder and related methods and uses. The present invention also relates to an expression construct or viral vector encoding an agent that increases Nato3 expression and/or activity and a host cell comprising said vector. The present invention also relates to a dopaminergic neuron or a dopaminergic progenitor comprising an expression construct encoding an agent that increases Nato3 expression and/or activity and a method of screening for a compound that improves dopaminergic function in a dopaminergic neuron.
Resumen de: WO2025144847A1
The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.
Resumen de: CN122768451A
0001 本发明属于神经退行性疾病治疗技术领域，具体涉及通过调控神经元Sortilin‑1（SORT1）蛋白的表达或功能活性，预防、治疗阿尔茨海默病（Alzheimer's Disease,·AD）的方法与药物组合物；同时涉及调控神经元‑小胶质细胞信号通路，维持神经元内体稳态、抑制小胶质细胞异常促炎活化、减轻神经炎症、保护神经元功能的技术方案。
Resumen de: CN122772104A
本发明提供了一种抗eMTBR‑tau243蛋白片段的单克隆抗体及其应用和产品，涉及生物技术领域。本发明提供的抗eMTBR‑tau243蛋白片段的单克隆抗体，能够特异性结合tau蛋白片段（aa225‑242），以及包含这个片段的tau蛋白片段（aa1‑256）以及全长tau蛋白（2N4R，aa1‑441），能够用于上述蛋白检测产品的制备。
Resumen de: KR20260138113A
본 발명은 단백질의 초기 응집 거동을 관찰할 수 있는 단백질의 응집 거동 관찰 장치 및 이를 이용한 단백질의 응집 거동 관찰 방법에 관한 것이다.
Resumen de: CN122772105A
发明公开了一种抗人Aβ40的抗体及其应用。所述抗体含重链可变区VH和轻链可变区VL；所述VH包含HCDR1、HCDR2和HCDR3，所述VL包含LCDR1、LCDR2和LCDR3；所述HCDR1‑HCDR3分别包含如SEQ ID NO:1‑3所示的氨基酸序列，所述LCDR1‑LCDR3分别包含如SEQ ID NO:4‑6所示的氨基酸序列。本发明的抗体灵敏性高、特异性好，基于该抗体对人Aβ40进行免疫检测，操作简单、灵敏度高、特异性强，可实现人Aβ40的快速检测，对评估人Aβ40具有重要意义。
Resumen de: CN122775828A
0001 本发明公开一种用于加工黄精的综合质量评价方法及在制备抗衰老产品中的应用。本发明的方法通过主客观权重协同优化与数据标准化处理构建科学评价模型，采用合适的综合评分法实现了对加工黄精的综合质量评价，进而指导工艺参数优化，同时提升主要活性成分保留率与稳定性，实现质量与效率的双重提升。本发明还进行了加工黄精的提取物在改善衰老动物记忆下降中的功效研究，通过构建的具有阿尔茨海默病特征的动物模型的功效相关研究结果表明，包含黄精粗多糖或黄精粗皂苷的黄精加工产品能够有效改善运动障碍、认知功能障碍和脑区Aβ病理性斑块的蓄积，同时具有显著的脑部细胞凋亡抑制作用。
Resumen de: CN122772974A
本发明涉及生物医药技术领域，尤其是涉及基于SERPING1的PASC相关心血管系统症状风险评估应用。本发明提供了一种以SERPING1为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: CN122772976A
0001 本发明涉及生物医药技术领域，尤其是涉及基于PRDX4的PASC相关心血管系统症状风险评估应用。本发明提供了一种以PRDX4为核心分子标志物的风险评估体系，该体系能够在常规检测手段难以提供充分解释的情况下，为PASC相关心血管系统症状风险评估提供客观、可量化的分子层面参考依据。
Resumen de: US20260276634A1
The present invention relates to an in vitro method for evaluating the state of intestinal permeability of a subject and, consequently, for the diagnosis of diseases or dysfunctions associated with intestinal hyper-permeability. More specifically, the procedure allows measuring using a common food component the amount of dietary antigen that can traverse a dysfunctional intestine. The procedure allows for the development of analytical products and processes within the framework of the medical devices industry.
Resumen de: WO2026192282A1
An object of the present invention is to provide a method for recommending a treatment candidate group suitable for treatment with anti-amyloid antibody therapeutics by obtaining quantitative protein analysis data from blood and selecting a patient group at high risk of conversion to dementia.
Resumen de: US20260276648A1
Methods for identifying tumor tissue and determining a margin of a tumor to be resected in a subject are disclosed within. The methods utilize guanidinoacetic acid (GAA) as a tissue biomarker of malignant brain tumors. The presently disclosed subject matter further relates to methods for providing a diagnosis or prognosis about a cancer in a subject.
Resumen de: US20260272907A1
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase (“BTK”) inhibitors for treatment of subjects with relapsing multiple sclerosis.
Nº publicación: US20260276659A1 17/09/2026
Solicitante:
MASSACHUSETTS GEN HOSPITAL [US]
The General Hospital Corporation
Resumen de: US20260276659A1
A method includes estimating a value of a parameter indicative of an age or lifespan of a population of red blood cells of a subject, estimating a value of average glucose (AG) of the subject based on (i) the value of the parameter and (ii) a value indicative of an amount of glycated hemoglobin (HbA1c) of the subject, and providing information for treatment or diagnosis of a hyperglycemia condition of the subject based on the estimated value of AG.
BOPI
Sede Electrónica
